Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 508/1999, ANNEX III. (See end of Document for details)

ANNEX III

LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES USED IN VETERINARY MEDICINAL PRODUCTS FOR WHICH PROVISIONAL MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

- 1. Anti-infectious agents
- 1.1. Chemotheurapeutics

1.1.2. Benzenesulphonamides

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Clorsulon	Clorsulon	Bovine	50 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			150 μg/kg	Liver	
			400 μg/kg	Kidney	

1.2. Antibiotics

1.2.1. Beta-lactamase inhibitors

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Clavulanic acid	Clavulanic acid	Bovine, ovine	200 μg/kg	Milk	Provisional MRLs expire on 1 July 1999
		Bovine, ovine, porcine	200 μg/kg	Muscle	
			200 μg/kg	Fat	
			200 μg/kg	Liver	
			200 μg/kg	Kidney	

1.2.2. Macrolides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Erythromycin	MRLs apply to all microbiologica	Bovine, ovine	40 μg/kg	Milk	Provisional MRLs expire

	active residues expressed as erythromycin equivalent				on 1 June 2000
		Bovine, ovine, porcine, poultry	400 μg/kg	Muscle	
			400 μg/kg	Fat	
			400 μg/kg	Liver	
			400 μg/kg	Kidney	
		Poultry	200 μg/kg	Eggs	
Josamycin	Josamycin	Chicken	200 μg/kg	Muscle	Provisional MRLs expire on 1 July 2000
			200 μg/kg	Fat	
			200 μg/kg	Liver	
			400 μg/kg	Kidney	
			200 μg/kg	Eggs	

1.2.5. Aminoglycosides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Aminosidine	Aminosidine	Bovine, porcine, rabbits, chicken	500 μg/kg	Muscle	Provisional MRLs expire on 1 July 2000
			1 500 μg/kg	Liver	
			1 500 μg/kg	Kidney	
Apramycin	Apramycin	Bovine	1 000 μg/kg	Muscle	Provisional MRLs expire on 1 July 1999
		For use in non-lactating cattle only	1 000 μg/kg	Fat	
			10 000 μg/kg	Liver	
			20 000 μg/kg	Kidney	

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 508/1999, ANNEX III. (See end of Document for details)

		Porcine	1 000 μg/kg	Muscle	
			1 000 μg/kg	Skin and fat	
			1 000 μg/kg	Liver	
			5 000 μg/kg	Kidney	
Dihydrostrepto	n Djhjrd rostrepto	nBywime, ovine	200 μg/kg	Milk	Provisional MRLs expire on 1 June 2000
		Bovine, ovine, porcine, poultry	500 μg/kg	Muscle	
			500 μg/kg	Fat	
			500 μg/kg	Liver	
			1 000 μg/kg	Kidney	
Gentamicin	Gentamicin	Bovine	100 μg/kg	Milk	Provisional MRLs expire on 1 June 2000
		Bovine, porcine	100 μg/kg	Muscle	
			100 μg/kg	Fat	
			200 μg/kg	Liver	
			1 000 μg/kg	Kidney	
Neomycin (including framycetin)	Neomycin	Bovine, ovine, caprine	500 μg/kg	Milk	Provisional MRLs expire on 1 June 2000
		Bovine, ovine, caprine, porcine, chicken, turkey, duck	500 μg/kg	Muscle	
			500 μg/kg	Fat	
			500 μg/kg	Liver	
			5 000 μg/kg	Kidney	
		Chicken	500 μg/kg	Eggs	
Spectinomycin	Spectinomycin	Bovine	200 μg/kg	Milk	Provisional MRLs expire

					on 1 July 2000
		Bovine, porcine, poultry	300 μg/kg	Muscle	
			500 μg/kg	Fat	
			2 000 μg/kg	Liver	
			5 000 μg/kg	Kidney	
Streptomycin	Streptomycin	Bovine, ovine	200 μg/kg	Milk	Provisional MRLs expire on 1 June 2000
		Bovine, ovine, porcine, poultry	500 μg/kg	Muscle	
			500 μg/kg	Fat	
			500 μg/kg	Liver	
			1 000 μg/kg	Kidney	

1.2.6. Quinolones

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Decoquinate	Decoquinate	Bovine, ovine	500 μg/kg	Muscle	Provisional MRLs expire on 1 July 2000
			500 μg/kg	Fat	
			500 μg/kg	Liver	
			500 μg/kg	Kidney	
Enrofloxacin	Sum of enrofloxacin and ciprofloxacin	Ovine	100 μg/kg	Muscle	Provisional MRLs expire on 1 July 1999
			100 μg/kg	Fat	
			300 μg/kg	Liver	
			200 μg/kg	Kidney	
Flumequine	Flumequine	Bovine, ovine,	50 μg/kg	Muscle	Provisional MRLs expire

Document Generated: 2023-12-04

Changes to legislation: There are currently no known outstanding effects for the

Changes to legislation: There are currently no known outstanding effects for the	
Commission Regulation (EC) No 508/1999, ANNEX III. (See end of Document for detail	ils)

		porcine, chicken			on 1 January 2000
			50 μg/kg	Fat or skin and fat	
			100 μg/kg	Liver	
			300 μg/kg	Kidney	
		Salmonidae	150 μg/kg	Muscle and skin	
Marbofloxacin	Marbofloxacin	Bovine	150 μg/kg	Muscle	Provisional MRLs expire on 1 July 2000
			50 μg/kg	Fat	
			150 μg/kg	Liver	
			150 μg/kg	Kidney	
			75 μg/kg	Milk	
		Porcine	150 μg/kg	Muscle	
			50 μg/kg	Skin and fat	
			150 μg/kg	Liver	
			150 μg/kg	Kidney	

1.2.9. Polymyxins

Phamarcolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Colistin	Colistin	Bovine, ovine	50 μg/kg	Milk	Provisional MRLs expire on 1 July 2000
		Bovine, ovine, porcine, chicken, rabbits	150 μg/kg	Muscle	
			150 μg/kg	Fat	
			150 μg/kg	Liver	
			200 μg/kg	Kidney	
		Chicken	300 μg/kg	Eggs	

1.2.10. Penicillins

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 508/1999, ANNEX III. (See end of Document for details)

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Penethamate	Benzylpenicilli	nOvine	50 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			50 μg/kg	Fat	
			50 μg/kg	Liver	
			50 μg/kg	Kidney	
			4 μg/kg	Milk	
		Porcine	50 μg/kg	Muscle	
			50 μg/kg	Fat	
			50 μg/kg	Liver	
			50 μg/kg	Kidney	

1.2.11. Florfenicol and related compounds

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Florfenicol	Sum of florfenicol and its metabolites measured as florfenicol- amine	Fish	1 000 μg/kg	Muscle and skin in natural proportions	Provisional MRLs expire on 1 July 2001

2. Antiparasitic agents

2.1. Agents acting against endoparasites

2.1.2. Benzimidazoles and pro-benzimidazoles

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Albendazole sulphoxide	Sum of albendazole, albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino	Bovine, ovine	100 μg/kg	Milk	Provisional MRLs expire on 1 January 2000

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 508/1999, ANNEX III. (See end of Document for details)

	sulphone, expressed as albendazole				
		Bovine, ovine, pheasant	100 μg/kg	Muscle	
			100 μg/kg	Fat	
			1 000 μg/kg	Liver	
			500 μg/kg	Kidney	
Netobimin	Sum of netobimin and albendazole and metabolites of albendazole measured as 2-aminobenzimidazole sulphone	Bovine, ovine, caprine	100 μg/kg	Muscle	Provisional MRLs expire on 31 July 1999
			100 μg/kg	Fat	
			1 000 μg/kg	Liver	
			500 μg/kg	Kidney	
			100 μg/kg	Milk	

2.2. Agents acting against ectoparasites

2.2.1. Formamidines

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Amitraz	Sum of amitraz and all metabolites containing the 2,4- DMA moeity, expressed as amitraz	Bees	200 μg/kg	Honey	Provisional MRLs expire on 1 July 1999

Iminophenyl thiazolidine derivative 2.2.2.

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Cymiazole	Cymiazole	Bees	1 000 μg/kg	Honey	Provisional MRLs expire on 1 July 1999

Pyretrin and pyrethroids 2.2.3.

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Cyfluthrin	Cyfluthrin	Bovine	10 μg/kg	Muscle	Provisional MRLs expire on 1 January 2001
			50 μg/kg	Fat	
			10 μg/kg	Liver	
			10 μg/kg	Kidney	
			20 μg/kg	Milk	
				Further provisions in Council Directive 94/29/EC are to be observed (OJ L 189, 23.7.1994, p. 67)	

2.2.4. Organophosphates

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Azamethiphos	Azamethiphos	Salmonidae	100 μg/kg	Muscle and skin in natural proportions	Provisional MRLs expire on 1 June 1999

Acyl urea derivates 2.2.5.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 508/1999, ANNEX III. (See end of Document for details)

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Teflubenzuron	Teflubenzuron	Salmonidae	500 μg/kg	Muscle and skin in natural proportions	Provisional MRLs expire on 1 July 1999

Agents acting against endo- and ectoparasites 2.3.

2.3.1. Avermectins

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Moxidectin	Moxidectin	Equidae	50 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			500 μg/kg	Fat	
			100 μg/kg	Liver	
			50 μg/kg	Kidney	

3. Agents acting on the nervous system

3.2. Agents acting on the autonomic nervous system

3.2.1. β 2 sympathomimetic agents

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Clenbuterol hydrochloride	Clenbuterol	Bovine	0,1 μg/kg	Muscle	Provisional MRLs expire on 1 July 2000
		Indication: solely for tocolysis in parturient cows	0,5 μg/kg	Liver	
			0,5 μg/kg	Kidney	
			0,05 μg/kg	Milk	
		Equidae	0,1 μg/kg	Muscle	
		Indications: tocolysis and	0,5 μg/kg	Liver	

	the treatment of respiratory ailments			
		0,5 μg/kg	Kidney	

5. Anti-inflammatory agents

5.1. Nonsteroidal anti-inflammatory agents

5.1.1. Arylpropionic acid derivative

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Carprofen	Carprofen	Bovine	500 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			500 μg/kg	Fat	
			1 000 μg/kg	Liver	
			1 000 μg/kg	Kidney	
		Equidae	50 μg/kg	Muscle	
			100 μg/kg	Fat	
			1 000 μg/kg	Liver	
			1 000 μg/kg	Kidney	

5.1.2. Enolic acid derivates

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Meloxicam	Meloxicam	Bovine	25 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			60 μg/kg	Liver	
			35 μg/kg	Kidney	

Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EC) No 508/1999, ANNEX III.